Boston Scientific Corpora... (BSX)
NYSE: BSX
· Real-Time Price · USD
104.96
2.01 (1.95%)
At close: May 15, 2025, 3:06 PM
Boston Scientific Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular Revenue | 10.76B | 8.82B | 8.16B | 4.86B | 3.88B | 4.21B | 3.78B | 3.5B | 3.62B | 3.22B | 2.95B | 2.87B | 3.27B |
| Cardiovascular Revenue Growth | +21.95% | +8.06% | +67.99% | +25.34% | -7.89% | +11.41% | +7.91% | -3.23% | +12.43% | +8.94% | +3.00% | -12.35% | n/a |
| MedSurg Revenue | 5.99B | 5.42B | 5.06B | 3.72B | 3.07B | 3.31B | 3.01B | 3.38B | 3.2B | 2.67B | 2.36B | 2.3B | n/a |
| MedSurg Revenue Growth | +10.53% | +7.22% | +35.79% | +21.46% | -7.29% | +9.98% | -10.96% | +5.40% | +20.04% | +13.14% | +2.65% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.6B | 1.61B | 1.56B | 1.45B | 1.36B | 1.38B | 1.24B | 1.35B | 1.22B | 1.16B | 1.13B | 1.17B | 1.06B | 1.15B | 1.07B | 1.12B | 1.02B | 1.03B | 984M | 798M | 978M | 1.09B | 1.01B | 968M | 869M | 953M | 870M | 886M | 860M | 886M | 800M | 815M | 794M | 831M | 772M | 779M | 716M | 777M | 729M | 700M | 668M |
| Selling, General, and Administrative Revenue Growth | -0.93% | +3.20% | +8.02% | +6.01% | -1.09% | +11.03% | -8.27% | +11.44% | +4.47% | +2.74% | -2.83% | +9.91% | -8.07% | +8.16% | -4.91% | +10.01% | -0.78% | +4.37% | +23.31% | -18.40% | -10.44% | +7.91% | +4.55% | +11.39% | -8.81% | +9.54% | -1.81% | +3.02% | -2.93% | +10.75% | -1.84% | +2.64% | -4.45% | +7.64% | -0.90% | +8.80% | -7.85% | +6.58% | +4.14% | +4.79% | n/a |
| Research and Development Revenue | 443M | 459M | 407M | 383M | 366M | 363M | 356M | 359M | 337M | 330M | 339M | 335M | 319M | 320M | 310M | 298M | 276M | 286M | 315M | 242M | 300M | 309M | 306M | 280M | 280M | 288M | 289M | 275M | 261M | 264M | 254M | 244M | 235M | 256M | 232M | 222M | 210M | 244M | 221M | 220M | 192M |
| Research and Development Revenue Growth | -3.49% | +12.78% | +6.27% | +4.64% | +0.83% | +1.97% | -0.84% | +6.53% | +2.12% | -2.65% | +1.19% | +5.02% | -0.31% | +3.23% | +4.03% | +7.97% | -3.50% | -9.21% | +30.17% | -19.33% | -2.91% | +0.98% | +9.29% | 0.00% | -2.78% | -0.35% | +5.09% | +5.36% | -1.14% | +3.94% | +4.10% | +3.83% | -8.20% | +10.34% | +4.50% | +5.71% | -13.93% | +10.41% | +0.45% | +14.58% | n/a |